All In Biotech

NDA 021029 · Merck Sharp Dohme

Temodar

Temozolomide · Oral · Alkylating Drug

NovelAccelerated approvalPriority reviewOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Sep 14, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Aug 11, 1999

Approved uses

6

Original approval plus efficacy supplements

Registered trials

1,139

125 Phase 3, 153 recruiting

FAERS reports

21,320

17,250 serious, 4,502 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 20, 2026.

TEMODAR is an alkylating drug indicated for the treatment of adults with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma. ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 ) 1.1 Newly Diagnosed Glioblastoma TEMODAR is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMODAR is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma.

Mechanism: Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to DNA alkylation, mainly at the O 6 and N 7 positions of guanine, which causes DNA double strand breaks and results in programmed cell death.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • TEMODAR · TEMOZOLOMIDE 140MG · CAPSULE, ORAL · Discontinued · TE AB
  • TEMODAR · TEMOZOLOMIDE 100MG · CAPSULE, ORAL · Discontinued · TE AB
  • TEMODAR · TEMOZOLOMIDE 5MG · CAPSULE, ORAL · Discontinued · TE AB
  • TEMODAR · TEMOZOLOMIDE 180MG · CAPSULE, ORAL · Discontinued · TE AB
  • TEMODAR · TEMOZOLOMIDE 250MG · CAPSULE, ORAL · Discontinued · TE AB
  • TEMODAR · TEMOZOLOMIDE 20MG · CAPSULE, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Temozolomide" as an intervention, any sponsor and status, largest first.

All 1,139 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • disease progression1,895
  • off label use1,833
  • death1,811
  • thrombocytopenia1,592
  • product use in unapproved indication1,474
  • nausea1,332
  • drug ineffective1,270
  • fatigue1,050
  • neutropenia1,041
  • vomiting991
  • malignant neoplasm progression944
  • febrile neutropenia839

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004149
2005291
2006304
2007579
2008747
2009441
2010403
2011462
2012736
2013671
2014617
2015779
2016852
20171,041
20181,205
20191,170
20201,483
20211,560
20221,994
20231,746
20241,527
20251,524
20261,039

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,301 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.